国泰海通证券研报指出，天坛生物采浆量快速增长，新产能投放有望带来生产效率的提升，新产品获批有望带来血浆综合利用率的提升，维持“增持”评级。公司及各所属企业依托国药集团与各地战略合作背景，积极争取各级政府及卫生健康行政主管部门支持。截至目前公司下辖7 张牌照共有在营浆站达85家，在建浆站达22 家，2024年采浆量达2781吨。认为目前公司拥有7 张牌照，分布在全国多个区域，在即将到来的十五五期间仍有机会获取更多浆站。公司通过内部技术共享合理布局下属子公司科研品种，采用集中研发、分散注册的科研模式缩短研发时间，加速推进新产品研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.